Literature DB >> 23030498

Phosphorylation-dependent protein-protein interaction modules as potential molecular targets for cancer therapy.

Nobumoto Watanabe1, Hiroyuki Osada.   

Abstract

Protein phosphorylation is a key event in signal transduction pathways. When upstream signals are stimulated, protein kinases are activated and phosphorylate their substrates, modulating their localization, conformation, and activity. In some cases, phosphorylated substrates become recognizable to other proteins-such interactions transduce and propel the signal onward. Certain domains specifically recognize phosphorylated residues of proteins, regulating cell growth and differentiation. Because the proteins that contain these domains also mediate diseases that are caused by dysregulated signal transduction, small molecules that inhibit such motifs are attractive candidates for the treatment of diseases, such as cancer. In this review, we summarize the domains that recognize phosphorylated proteins, particularly serine- and threonine-phosphorylated sequences in target proteins. In addition, we introduce a high-throughput screen that we developed to identify small-molecule inhibitors of phosphorylation-dependent protein-protein interactions. An example is presented, and the potential uses of this system are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23030498     DOI: 10.2174/138945012803530035

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  13 in total

Review 1.  Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.

Authors:  Tom Rouwette; Luca Avenali; Julia Sondermann; Pratibha Narayanan; David Gomez-Varela; Manuela Schmidt
Journal:  Channels (Austin)       Date:  2015-06-03       Impact factor: 2.581

2.  Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression.

Authors:  Long Chen; Tingyi Wei; Xiaoxing Si; Qianqian Wang; Yan Li; Ye Leng; Anmei Deng; Jie Chen; Guiying Wang; Songcheng Zhu; Jiuhong Kang
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

3.  Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.

Authors:  Pierre C Havugimana; Raghuveera Kumar Goel; Sadhna Phanse; Ahmed Youssef; Dzmitry Padhorny; Sergei Kotelnikov; Dima Kozakov; Andrew Emili
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

Review 4.  Pathological implication of protein post-translational modifications in cancer.

Authors:  Sheng Pan; Ru Chen
Journal:  Mol Aspects Med       Date:  2022-04-07

Review 5.  Targeting protein-protein interactions as an anticancer strategy.

Authors:  Andrei A Ivanov; Fadlo R Khuri; Haian Fu
Journal:  Trends Pharmacol Sci       Date:  2013-05-29       Impact factor: 14.819

6.  Ecto-protein kinases and phosphatases: an emerging field for translational medicine.

Authors:  Garif Yalak; Yigal H Ehrlich; Bjorn R Olsen
Journal:  J Transl Med       Date:  2014-06-12       Impact factor: 5.531

7.  Combined phosphoproteomics and bioinformatics strategy in deciphering drug resistant related pathways in triple negative breast cancer.

Authors:  Xinyu Deng; Morris Kohanfars; Huan Ming Hsu; Puneet Souda; Joe Capri; Julian P Whitelegge; Helena R Chang
Journal:  Int J Proteomics       Date:  2014-11-13

Review 8.  Heat shock protein 27 phosphorylation state is associated with cancer progression.

Authors:  Maria Katsogiannou; Claudia Andrieu; Palma Rocchi
Journal:  Front Genet       Date:  2014-10-06       Impact factor: 4.599

Review 9.  The roles of PIKE in tumorigenesis.

Authors:  Qi Qi; Keqiang Ye
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

Review 10.  Emerging role of cell polarity proteins in breast cancer progression and metastasis.

Authors:  Sudipa June Chatterjee; Luke McCaffrey
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.